Background: The major goal of antiretroviral therapy (ART) is immunological recovery and virological suppression. Immunological and virological response in People Living with HIV (PLHIV) receiving ART has to be monitored to assess the treatment response, diagnosing treatment failure and switching antiretroviral therapy. Aims & objective: To assess the immunological and virological response to ARTamong Human Immunodeficiency Virus (HIV) infected individuals. Material & method: This is a cross-sectional study including people living with HIV (PLHIV) receiving ART for at least 6 months and was conducted from January 2023 to December 2023. The socio-demographic profile, CD4 count and viral load were analysed. Results: 150 patients receiving ARTwere included in the study with 118 (78.66%) patients had virological suppression and immunological recovery. 7 patients (4.6%) had a virological failure. 25 patients (16.6%) had an immunological failure. The Mean ages of patients were 34.70±12.06 years at diagnosis. The majority of the patients were male 102 (68%). The mean CD4 count at baseline was 304.03±244.08 cells/µL. The mean CD4 count after treatment increased from 304.03cells/µL to 513.22 cells/µL after 6 months of start of antiretroviral therapy. Conclusion: There are optimal CD4 recovery and virological suppression as expected with antiretroviral therapy use. ART regimen adherence is important to decrease the prevalence of ART regimen treatment failure.